Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupportContact
Search
Close

Circuit Split on FCA Causation Deepens with Upcoming First Circuit Ruling

By Jonathan H. Ferry on September 28, 2023
Email this postTweet this postLike this postShare this post on LinkedIn
Circuit Split on FCA Causation Deepens with Upcoming First Circuit Ruling

The First Circuit will decide the causation standard required in False Claims Act (FCA) cases predicated on the Anti-Kickback Statute (AKS), deepening a circuit split on the issue and potentially teeing up Supreme Court intervention.

U.S. District Judge Nathaniel Gorton asked the First Circuit to review his recent ruling that the government need not prove a “but for” causal connection between an AKS violation and an allegedly false claim. In certifying this decision for interlocutory appeal, Judge Gorton acknowledged that there is “substantial ground for difference of opinion” on the standard, likely referencing the growing divide between circuit courts on this outcome-determinative issue.  

Judge Gorton’s ruling pauses United States v. Teva Pharmaceuticals USA Inc. — a sprawling FCA case wherein the government accuses Teva Pharmaceuticals of using illegal kickbacks to boost its drug sales, thereby causing Medicare to pay $1.49 billion in tainted claims. Specifically, the government alleges that Teva paid two charitable foundations illegal co-pay subsidies in connection with the sale of Copaxone, a multiple sclerosis drug. Teva estimates its potential exposure in this case may exceed $10 billion — “an enterprise-threatening amount.”

Judge Gorton denied Teva’s argument that the government must demonstrate “but for” causation, instead relying on ambiguous language from the First Circuit requiring only a “sufficient causal connection” between an AKS violation and an alleged false claim. Judge Gorton did not clarify what constitutes a “sufficient causal connection.”

At issue is language in the AKS added by the Affordable Care Act in 2010 that states “a claim that includes items or services resulting from a violation of [the AKS] constitutes a false or fraudulent claim for purposes of” the FCA. Both the Sixth and Eighth circuits interpreted the phrase “resulting from” as requiring “but for” causation — i.e., requiring the government to show that the defendant would not have submitted the alleged false claim but for the AKS violation. The Third Circuit, however, construed this language as allowing something less than “but for” causation — requiring only a “link” between the alleged kickback and the claim.

The causation standard provides a crucial check on the increasing use of alleged AKS violations as predicates for FCA liability. Both the government and relators’ counsel expansively interpret the causation requirement to drive enormous damages models in FCA cases based on tenuous connections between the alleged AKS violation and the actual submission of claims. The First Circuit could contain this overreach and set reasonable limitations on FCA liability by agreeing with the Sixth and Eighth circuits in requiring “but for” causation or otherwise delineate the rational nexus between the AKS violation and the submitted claims required in its upcoming review of the Teva case.  

Photo of Jonathan H. Ferry Jonathan H. Ferry

Jon Ferry brings his substantial experience as a federal prosecutor to assisting clients in False Claims Act litigation, government investigations and other enforcement actions, internal risk analysis and internal investigations.

Jon served as Assistant U.S. Attorney for the Western District of North Carolina…

Jon Ferry brings his substantial experience as a federal prosecutor to assisting clients in False Claims Act litigation, government investigations and other enforcement actions, internal risk analysis and internal investigations.

Jon served as Assistant U.S. Attorney for the Western District of North Carolina for over seven years. As the head of the Affirmative Civil Enforcement (ACE) program and the Healthcare Fraud Coordinator for the U.S. Attorney’s Office, Jon led and supervised numerous investigations in the areas of healthcare, financial services and other complex frauds. He has significant experience with the False Claims Act and other whistleblower actions, healthcare regulations (including the Anti-Kickback Statute and Stark Law), the Food Drugs and Cosmetics Act, and the Financial Institutions Reform, Recovery and Enforcement Act (FIRREA).

Read more about Jonathan H. FerryEmailJonathan's Linkedin Profile
Show more Show less
  • Posted in:
    Business and Commercial
  • Blog:
    Eye on Enforcement
  • Organization:
    Bradley Arant Boult Cummings LLP
  • Article: View Original Source

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS
The Library at LexBlog
  • About LexBlog
  • The Field We Built
  • Library at LexBlog
  • Our Beliefs
  • Our Team
  • Contact LexBlog
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • Get Started
  • Publishing Solutions
  • Compass
  • Submit a Request
  • Support Center
  • System Status
Copyright © 2026, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo